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Basal cell carcinomas (BCCs) and a subset of medulloblastomas are characterized by loss-
of-function mutations in the tumor suppressor gene, PTCH1. PTCH1 normally functions by
repressing the activity of the Smoothened (SMO) receptor. Inactivating PTCH1 mutations
result in constitutive Hedgehog pathway activity through uncontrolled SMO signaling. Tar-
geting this pathway with vismodegib, a novel SMO inhibitor, results in impressive tumor
regression in patients harboring genetic defects in this pathway. However, a secondary
mutation in SMO has been reported in medulloblastoma patients following relapse on vis-
modegib to date. This mutation preserves pathway activity, but appears to confer resis-
tance by interfering with drug binding.
Here we report for the first time on the molecular mechanisms of resistance to vismodegib
in two BCC cases. The first case, showing progression after 2 months of continuous vismo-
degib (primary resistance), exhibited the new SMO G497W mutation. The second case,
showing a complete clinical response after 5 months of treatment and a subsequent pro-
gression after 11 months on vismodegib (secondary resistance), exhibited a PTCH1
nonsense mutation in both the pre- and the post-treatment specimens, and the SMO
D473Y mutation in the post-treatment specimens only. In silico analysis demonstrated
that SMOG497W undergoes a conformational rearrangement resulting in a partial obstruc-
tion of the protein drug entry site, whereas the SMO D473Y mutation induces a direct effect
on the binding site geometry leading to a total disruption of a stabilizing hydrogen bond
network. Thus, the G497W and D473Y SMO mutations may represent two different mech-
anisms leading to primary and secondary resistance to vismodegib, respectively.
ª 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.0; fax: þ39 040 569823.
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M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 3 8 9e3 9 73901. Introduction Exons 1-23 of PTCH1 and 8-10 of SMO were amplified byBasal cell carcinoma (BCC) is the most frequent skin cancer
with a recognized increasing incidence in the last 30 years.
(Flohil et al., 2013) Treatment of BCC mainly consists of local
approaches, surgery being the most effective one, followed
by radiotherapy, photodynamic therapy, and imiquimod as
alternative therapeutic strategies. (Rubin et al., 2005) Systemic
therapy for metastatic and locally advanced BCCs not
amenable to curative surgery or radiotherapy has been
recently added to the therapeutic arsenal, with the approval
by FDA and EMA of vismodegib, a small molecule inhibitor
of the Hedgehog (Hh) pathway. Indeed, BCC pathogenesis is
based on an inappropriate activation of the Hh pathway.
The Hh ligand binds the transmembrane receptor PatchedHo-
molog 1 (PTCH1) that in turn prevents the inhibition of the
transmembrane Smoothened (SMO) receptor. SMO signaling
results in the activation of GLI family zinc finger transcription
factors and their target genes such as Cyclin D1. PTCH1 inacti-
vatingmutations, characterizing>90% of BCCs, and activating
SMO mutations, even if less frequent, (Reifenberger et al.,
2005) can act as ligand-independent oncogenic drivers of
this disease. (Rubin et al., 2005) Vismodegib binds and inhibits
SMO, thus preventing systemic activation of the forward
signaling. Also, the significant antitumor activity of vismode-
gib in BCC strongly suggests the addiction of this tumor to
SMO activity. (Von Hoff et al., 2009).
Results of the pivotal phase II trial with vismodegib in met-
astatic or locally advanced BCCs showed a response rate of
30% and 43% in the two settings of disease, respectively.
(Sekulic et al., 2012) Median duration of response was 7.6
months.
Acquired resistance to vismodegib has been reported in
medulloblastomas where the drug, after an initial dramatic
response, rapidly turned into resistance. (Yauch et al., 2009)
This happened through the acquisition of the SMOD473Hmu-
tation which, according to the authors, prevents vismodegib
from binding without altering the ability of the receptor to
activate the downstream Hh pathway. (Yauch et al., 2009) To
our knowledge, however, no evidence of molecular mecha-
nisms associated with primary or acquired resistance to vis-
modegib in BCCs has been reported to date. Accordingly, in
this study we present and discuss for the first time clinical,
molecular and in silico evidence of primary and acquired
SMO mutation-mediated resistance to vismodegib in BCCs.2. Materials and methods
2.1. PTCH1 and SMO mutational analysis
Formalin-fixed paraffin-embedded (FFPE) tumor specimens of
pre-treatment liver metastasis, primary tumor and node
metastasis (first case), and of both pre-treatment primary tu-
mor and recurrence arisen on vismodegib regimen (second
case) were reviewed and subjected to micro-dissection under
microscopy control. Genomic DNA was extracted using the
Qiamp FFPE DNA kit (Qiagen, Chatsworth, CA), followingman-
ufacturer’s instructions.PCR; all PCR primer sequences are available upon request.
The PCR products were subjected to direct sequencing using
an ABI Prism 3500 DX Genetic Analyzer (Applied Biosystems,
Foster City, CA, USA), and then evaluated by means of the
ChromasPro software.
2.2. In silico experiments
The Amber ff03 force field (Duan et al., 2003) was used to
parametrize all protein structures. The atomic partial charges
for vismodegibwere obtained using the RESP procedure (Bayly
et al., 1993), and the electrostatic potentials were produced by
single-point quantummechanical calculations at the Hartree-
Fock level with a 6-31G* basis set, using the Merz-Singh-
Kollman van der Waals parameters. (Singh and Kollman,
1984; Besler et al., 1990) Eventual missing force field parame-
ters for the inhibitor molecule were generated using the Ante-
chamber tool (Wang et al., 2006) of Amber 12 (Case et al., 2012)
and the general AMBER force field (GAFF) (Wang et al., 2004) for
rational drug design.
The structures of each SMOproteins in complexwith vismo-
degib were obtained exploited a well-validated procedure re-
ported in details in our previous works. (Bozzi et al., 2013;
Laurini et al., 2013; Conca et al., 2013; Dileo et al., 2011; Pierotti
et al., 2011) However, since SMO is a transmembrane receptor
protein, each protein/drug complex was inserted into a lipid
membrane structure prior to solvation in an explicit water envi-
ronment. To the purpose, the CHARMM-GUI Lipid Builder web
application was employed. (Woolf and Roux, 1996; Jo et al.,
2007) The lipidic bilayer consisted in a 2:2 proportion of 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-
palmitoyl-2-oleoyl-sn- glycero-3-phosphoethanolamine (POPE).
The two sides (top and bottom) of the membrane were consti-
tutedby125and115 lipidmolecules, respectively.Theentiresys-
tem was parameterized using the lipid11 library (Skjevik et al.,
2012) of the ff03 force field.
Each system was then allowed to relax in a box of TIP3P
water molecules. (Jorgensen et al., 1983) The solvated systems
were minimized with a gradual decrease in the position re-
straints of the protein atoms. Finally, to achieve electroneu-
trality, a suitable number of neutralizing ions were added;
further, the solution ionic strength was adjusted to the phys-
iological value of 0.15 M by adding the required amounts of
Naþ and Cl ions. After energy minimization of the added
ions for 1500 steps, the entire water/ion box was equilibrated
via 2ns constant volume/constant temperature (NVT)molecu-
lar dynamics (MD) simulations. Further unfavorable interac-
tions within the structures were relieved by imposing
progressively smaller positional restraints on the protein/in-
hibitor complex (from 25 to 0 kcal/(mol A2) for a total of 5 ns
of MD simulations. Each hydrated complex system was then
gradually heated to 310 K in three intervals, allowing a 2 ns in-
terval per each 100 K, and then equilibrated for 5 ns at 310 K.
Finally, starting from each MD equilibrated system 50 ns of
data collection runs were carried out to estimate the corre-
sponding free energy of binding.
The production MD simulations were performed in the
constant pressure/constant temperature (NPT) ensemble at
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et al., 1984) with an integration time step of 2 fs, and the appli-
cations of the Shake algorithm. (Ryckaert et al., 1977) Long-
range nonbonded van der Waals interactions were truncated
by using a dual cutoff of 9 and 13 A, respectively, where en-
ergies and forces due to interactions between 9 and 13 A
were updated every 20-time steps. The particle mesh Ewald
method (Toukmaji et al., 2000) was used to treat the long-
range electrostatics. For the calculation of the binding free en-
ergy between SMO and vismodegib in water, a total of 50,000
snapshots were saved during the MD data collection period
described above.
The free energies of binding DGbind for the wild-type (WT)
and mutant SMO/vismodegib complexes were obtained using
an extensively validated procedure based on the Molecular
Mechanics/PoissoneBoltzmann Surface Area (MM-PBSA)
methodology. (Bozzi et al., 2013; Laurini et al., 2013; Conca
et al., 2013; Dileo et al., 2011; Pierotti et al., 2011; Gibbons
et al., 2014) Accordingly, DGbind values were calculated for
equilibrated structures extracted from the corresponding MD
trajectories. The average value of DGbind was estimated as
the sum of different energetic contributions, corresponding
to the average molecular mechanics energies
(DEMM ¼ DEele þ DEvdW), the average solvation free energy
(DGsolv ¼ DGsolv,pol þ DGsolv,nonpol), and the entropic contribu-
tion (TDS). The molecular mechanics energies (DEMM) were
evaluated from a single 50 ns MD trajectory of each recep-
tor/inhibitor complex. The solvation energies were obtained
solving the PoissoneBoltzmann equation for the polar part
(DGsolv,pol) plus a non-polar contribution (DGsolv,nonpol), propor-
tional to the solvent-accessible surface area and including the
entropy cost of creating a solute-size cavity in the solvent.
Finally, the variation of entropy upon binding was evaluated
by utilizing the quasi-harmonic approach. (Andricioaei and
Karplus, 2011).
A per residue binding free energy decomposition was per-
formed exploiting the MD trajectory of each complex. This
analysis was carried out using the MM/GBSA approach, (Tsui
and Case, 2000; Onufriev et al., 2000) and was based on the
same snapshots used in the binding free energy calculation.
The steered molecular dynamics (SMD) simulations
(Isralewitz et al., 2001) required to pull off the inhibitor from
its binding site were performed using snapshots randomly
taken from the MD equilibrated runs as initial structures.
The center of mass of vismodegib was chosen as the acting
point for the pulling force. Harmonic constraints were applied
to the Ca atoms of all helices in the SMO, while the exponent
appearing in the harmonic constraint energy functions was
set to the value of 2. The force constant and velocity used in
all SMD simulations were 4 kcal mol1 A2 (277.9 pN A1)
and 0.0001 A timestep1 (0.030 A ps1), respectively. With
these settings, 3.0 nmwere covered in 1000 ps of SMD simula-
tion. The same parameters were exploited to simulate the en-
try process of vismodegib into the SMO binding pocket.
The entire MM/PBSA computational procedure was opti-
mized by integrating AMBER 12 in modeFRONTIER, (http://
www.esteco.com/home/mode_frontier/mode_frontier.htm) a
multidisciplinary and multi-objective optimization and
design environment, and run on the EURORA supercomputer
(CINECA, Bologna, Italy).3. Results
Two patients enrolled in a phase II trial with vismodegib for
metastatic and locally advanced BCC (ClinicalTrials.gov Iden-
tifier: NCT01367665) are reported and discussed in thiswork as
examples of primary and acquired resistance to the vismode-
gib, respectively.
3.1. Patient 1: a case of vismodeginb primary resistance
in BCCs
The first patient was an 82-years oldwoman presentingwith a
BCC metastatic to liver, lung and bones. After histological
confirmation of liver metastasis, she received radiation ther-
apy to lumbar (L2-L4) and cervical (C3) secondary lesions
and she started vismodegib 150 mg/die. After 2 months of
continuous treatment, CT scans showed disease progression
at all sites (primary resistance).
3.2. Patient 2: a case of vismodegib acquired resistance
in BCCs
The second patient was a 78-years oldman presenting with a
large (12 cm), ulcerated lesion of the supra-scapular skin on
which a diagnosis of BCCwas rendered (Figure S1, left panel).
Because a surgical approach would have led to substantial
morbidity, this patient was started on a 150 mg/day vismo-
degib regimen. The lesion dramatically reduced after the
first month, and a complete clinical response was obtained
5 months later (Figure S1, right panel). However, after 11
months on vismodegib, two subcutaneous nodules appeared
in the area of the previous lesion. Both lesions were
surgically removed and the histology was consistent with
recurrent BCC suggesting the development of an acquired
resistance.
3.3. PTCH1 is wild type in vismodegib primary
resistance and mutated in acquired resistance to SMO in
BCC
To explore possible mechanisms of Hh pathway activation in
these two BCC cases considered, we first performed PTCH1
sequencing. In the pre-treatment BCC liver metastasis of the
case showing primary resistance (patient 1), no PTCH1 muta-
tion was observed (Figure 1A). By contrast, the pre-treatment
primary biopsy of the case showing acquired resistance
(patient 2) revealed the PTCH1 nonsense mutation
CAG > TAG creating a premature STOP codon (pQ84) in the
exon 2 (Figure 1B). This PTCH1 mutation predicts translation
to a heavily truncated protein, causing loss of function of
the protein and preventing inhibition of SMO. As expected,
the same PTCH1mutationwas also observed in the recurrence
sample taken during vismodegib (Figure 1B).
3.4. Two distinct missense SMO mutations characterize
primary and secondary vismodegib resistance in BCCs
Next, we evaluated the SMO mutational status. In the case
showing primary resistance (patient 1), the analysis of pre-
Figure 1 e Pre-treatment BCC liver metastasis of the first case (patient 1, primary resistance) showed PTCH1 wild type gene (A) and the SMO
G49W mutation (C). Pre-treatment primary tumor and BCC recurrence of the second case (patient 2, acquired resistance) carried the nonsense
Q84Stop PTCH1 mutation (B) while the SMO D473Y mutation was observed only in the recurrence BCC sample (D).
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tion GGG > TGG at exon 9, leading to the amino acid substitu-
tion G497W in the corresponding protein (Figure 1C). Primary
tumor and node metastasis also exhibited the same SMO
missense mutation GGG > TGG at exon 9. By contrast, in the
pre-treatment primary BCC of the second case (acquired resis-
tance, patient 2), no SMO mutations were detected (Figure 1D,
left panel); however the sample obtained from the recurrence
on vismodegib showed the missense mutation GAC > TAC at
exon 8, leading to the single amino acid substitution D473Y
(Figure 1D, right panel) confirming the acquired resistance to
the inhibitor.
3.5. SMOG497W: a distal mutation that obstructs
vismodegib entry to SMO binding site leading to primary
BCC resistance
To gain mechanistic insight regarding the resistance posed by
the mutant SMO proteins we performed a thorough in silico
analysis of the wild type and both clinically relevant SMO
mutant alleles (Figure 2).
As shown in Table 1, the MM/PBSA-derived IC50 for the
SMOG497W/vismodegib complex is 69 nM, a value slightly
higher than the experimental/calculated IC50 derived for the
wild-type (WT) receptor (3 and 2.5 nM, respectively). This
result indicates only a moderate direct effect of the mutation
G497Won the protein affinity for the inhibitor, in keepingwith
a distal position of G497W with respect to the protein drug
binding site.
However, in the presence of the mutant residue the entire
protein region undergoes a conformational rearrangement,
ultimately resulting in a partially obstructed drug entry site.Our simulations of the binding process of vismodegib to
SMO indeed shows that the vismodegib link with the protein
binding pocket is substantially hindered in the presence of
the G497W mutation (Figure 3AeB and movies).
Supplementary data related to this article can be found
online at http://dx.doi.org/10.1016/j.molonc.2014.09.003
This fundamentally implies that, in time, the effective vis-
modegib concentration within the SMOG497W binding site is
significantly lower than in the case of the WT receptor.
Accordingly to our simulation, other molecular mechanisms
are likely contributing to the resistance of SMOG497W to vismo-
degib. A direct comparison of the WT/mutated protein struc-
tures in the area surrounding position 497 revealed that, in
the presence of the tryptophan mutant residue, the entire re-
gion undergoes a conformational rearrangement, thus result-
ing in a narrowing of the protein drug entry site (Figure 3A).
For this reason, in the presence of the G497Wmutation vismo-
degib might be less able to reach the protein binding pocket
and, hence, less effective in its inhibitory activity. Further,
as we can see from Figure 3B and 3C, not only quite a higher
force (and hence energy) is required to vismodegib to reach
its binding site in the presence of the mutant residue
(Figure 3C) but also, and perhaps even more interestingly,
contrarily to the WT case, for SMOG497W the drug has not yet
reached its correct orientation within the protein binding
pocket after the same time lag (Figure 3B andmovies). In prac-
tical terms this fundamentally might imply that, in time, the
effective vismodegib concentration within the SMOG497W
binding site is significantly lower than in the case of the WT
receptor and this, is our opinion, constitutes a novel and effec-
tive mechanism of drug primary resistance.
Figure 2 e Cross section of the 3D structure of the SMO receptor
embedded in a 1-hexadecanoyl-2-[(9Z)-octadecenoyl]-sn-glycero-3-
phosphocholine (POPC)/1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoethanolamine (POPE) (2:2) membrane model. Water is
shown as a light cyan surface, while NaD and ClL ions are visible as
green and purple spheres, respectively. Lipids are portrayed as ball-
and-sticks, the polar heads of POPC and POPE depicted in white
and cyan, respectively, while the corresponding hydrophobic tails are
colored green and salmon, respectively. The membrane solvent
accessible surface area is highlighted in transparent forest green. The
SMO receptor protein is shown as a red ribbon, the inhibitor binding
region being evidenced by a yellow sphere.
Table 1 e In silico estimation of free energy of binding (DGbind) for
wild type (WT), SMOD473H and SMOG497W mutant receptors in
complex with vismodegib. Errors are given in parenthesis as











WT 11.75 (0.11) e 2.5 3
D473H 9.27 (0.10) 2.48 159 e
G497W 9.78 (0.10) 1.97 69 e
a DDGbind ¼ DGbind,WT  DGbind,mutant. By definition, a negative
value of DDGbind indicates that the WT/vismodegib complex is
favored with respect to the mutated one, and vice versa.
b DGbind and the concentration of ligand that inhibits the kinase
activity by 50% (i.e., IC50) are related by the following fundamental
equation: DGbind ¼ -RTln 1/IC50. Thus, once DGbind for a given ki-
nase/inhibitor couple is estimated by MM-PBSA simulations, the
relative IC50 value is also known by virtue of this relationship.
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interferes with vismodegib binding and leads to secondary
BCC resistance
When considering vismodegib in complex with SMOD473Y, the
alternative mutant isoform of SMO detected in the patient
specimen with acquired BCC resistance, the calculated IC50
value is 159 nM. This translates into an almost two orders of
magnitude decrease in protein affinity to vismodegib with
respect to the WT receptor (Table 1), clearly revealing a direct
effect of the mutated residue on vismodegib binding. Notably,
D473 is involved with other two residues (R400 and H470) in a
pivotal network of hydrogen bonds that keeps the SMO bind-
ing pocket in the proper shape and stabilizes vismodegib bind-
ing (Figure 4AeB). The aromatic side chain of the 473Y residue
induces a considerable effect on the binding site geometry and
leads to the total disruption of the stabilizing hydrogen bond
network; hence, the inhibitor is shifted from its optimalposition (Figure 4B). In details, in the presence of the D473Y
mutation, a considerable effect on the binding site geometry
is induced, required for the proper accommodation of the res-
idue aromatic side chain, ultimately leading to the total
disruption of the stabilizing hydrogen bond network. The in-
hibitor is hence shifted from its optimal position, the only sur-
viving interaction with the receptor being an intermitted
hydrogen bond with Y394.
These evidences are substantiated by the corresponding
per residue energy deconvolution of the free energy of bind-
ing, as shown in Figure 4CeD. As we see, all receptor residues
mainly involved in vismodegib binding undergo a severe
reduction in the stabilizing contribution to inhibitor binding
in the presence of the mutation (Figure 4C). Analogously,
upon disruption of the hydrogen bond network among the
SMO triad residues, the relevant, favorable contribution to re-
ceptor/inhibitor binding plummets drastically (Figure 4D).4. Discussion
This study presents for the first time clinical, molecular and in
silico evidence of primary and acquired SMO mutation-
mediated resistance to vismodegib in BCC. Indeed, the true-
cut based assessment of the SMO G497W missense mutation
in the liver pre-treatmentmetastasis of the first patient exhib-
iting a progression of disease after twomonths on vismodegib
provides a good example of primary resistance to the drug. To
our knowledge, this SMO mutation has never been previously
described. However, its location in the most frequently
mutated SMO region in BCC (exons 8e10) where other SMO
mutations have already shown a constitutive ligand-
independent signal transduction, argues in favor of its onco-
genic role. (Xie et al., 1998) Furthermore, since the lack of a
PTCH1 inactivating mutation reinforced this assumption, we
sought to explore the effects exerted by this mutation on the
inhibitor binding to the mutated SMO protein. By in silico ex-
periments we demonstrated that in the presence of the
W497 residue the entire protein region undergoes a conforma-
tional rearrangement, which ultimately results in a partial
obstruction of the protein drug entry site. This obstruction,
Figure 3 e (A) Zoomed view of the SMOG497W binding site in complex with vismodegib. The receptor is shown as a secondary-structure colored
ribbon (orange, a-helices; purple, b-sheets; gray, coils). Vismodegib is portrayed as atom-colored sticks-and-balls (red, O; blue, N; green, Cl; S,
sulfur; gray, C). Residue W497 is evidenced as dark red sticks. Hydrogen atoms, water molecules, ions and counterions are omitted for clarity. (B)
SMD snapshots of vismodegib entering the receptor binding pocket. Vismodegib is highlighted by its green/red van der Waals surface. Hydrogen
atoms, ions, counterions and water molecules are omitted for clarity. (C) Rupture force vs. time during the entry process of vismodegib within the
WT (green) and SMOG497W (red) binding site.
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concentration within the SMOG497W binding site (lower than
that in the case of theWT receptor), gives amechanistic expla-
nation for a novel effective drug resistance. In this respect, the
presence of such a SMO mutation in BCC candidate to vismo-
degib should definitely be assessed in a greater number of tu-
mors with primary resistance to the inhibitor. This would
eventually allow defining SMOG497W as a possible biomarker
for drug resistance, ultimately resulting in the avoidance of
unnecessary toxicity effects and costs limitation to non-
responding patients.
Concerning the second patient, the presence of the PTCH1
inactivating mutation in the pre-treatment primary lesion
along with absence of SMO mutation could explain the com-
plete clinical response obtained after 6 months of continuous
vismodegib treatment. Indeed, loss of PTCH1 function by inac-
tivating mutations relieves normal SMO inhibition leading to
the activation of Hh targets genes. By contrast, the secondary
drug resistance observed after 11months is likely to be ascrib-
able to the appearance of the missense SMO D473Y substitu-
tion in the recurrence sample. Notably, another amino acidsubstitution of the same SMO aspartic acid (D473H) was desig-
nated as themechanism of vismodegib resistance inmedullo-
blastoma. (Yauch et al., 2009) More recently, the detrimental
role of D473 in SMO function has been found out by an elegant
in vitro study where, by replacing this aspartic acid residue
with every other amino acid, all mutants were resistant to vis-
modegib. (Dijkgraaf et al., 2011) In keepingwith these findings,
our analysis of the structural effects of the SMO D473Y clearly
revealed a direct and significant effect on the binding site ge-
ometry. The inhibitor is shifted from its optimal position
because the aromatic side chain of the 473Y residue causes
the total disruption of the stabilizing hydrogen bond network
involving the D473 with other two residues (R400 and H470).
As for G497W, this SMO point mutation should also be
confirmed inagreater seriesof BCCs inorder todefinitely claim
its role in secondary resistance to vismodegib. As a general
remark, we acknowledge that the presented evidences could
be considered only reasonably correlated to the resistance
phenotype, and indeed our analysis requires further confirma-
tion through functional analysis. Under this perspective, in vi-
tro and in vivo experiments are underway in our laboratories to
Figure 4 e (A) Zoomed views of the wild type (WT) and (B) SMOD473Y mutant binding sites in complex with vismodegib. In both panels, the
receptor secondary structure is outlined as a semi-transparent ribbon (orange, a-helices; purple, b-sheets; gray, coils). Vismodegib is portrayed as
atom-colored sticks-and-balls (red, O; blue, N; green, Cl; S, sulfur; gray, C). The triad of residues involved in the hydrogen-bond network are
highlighted colored sticks: R300, dark magenta; H470, olive drab; D/Y473, dark cyan. Y394 is also shown as dark red sticks. H-bonds are evidenced
as black lines. (C) Comparison of vismodegib binding energy contributions from WT (green) and D473Y (red) SMO residues. (D) Comparison
between hydrogen bond network stabilization energies for SMO residues belonging to the WT (green) and SMOD473Y triad residues in the relevant
vismodegib complexes. X denotes either D or Y residue at position 473.
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possible biomarkers for vismodegib resistance.
Similarly to medulloblastoma, our data further raise the
issue of overcoming the resistance due to mutation of the
drug target. Under this perspective, efforts aimed at identi-
fying second-generation drugs showing potent activity
against SMO mutants are mandatory. To this goal, a panel of
compounds has already been screened in vitro. Several prom-
ising antagonists able to inhibit tumor growth mediated by
drug-resistant SMOs were selected in murine allograft model
of medulloblastoma, (Dijkgraaf et al., 2011) that could be
tested also in BCC.
Another strategy worth pursuing is the inhibition of the Hh
pathway through other mechanisms, the activity of itracona-
zole or arsenic oxide in blocking vismodegib-resistant BCC
both in vitro and in vivo being prime examples. (Kim et al.,
2013, 2014).
A further alternative approach for facing vismodegib resis-
tance could consist in exploring other pathways interacting
with Hh signaling in BCC and leading to an SMO-
independent stimulation of Gli1 such as EGFR, (Eberl et al.,
2012) the atypical protein kinase C i/l, (Atwood et al., 2013)
the protein kinase A (Makinodan and Marneros, 2012) and,similarly to medulloblastoma, the PI3K pathway. (Dijkgraaf
et al., 2011; Buonamici et al., 2010).
Finally, a clinical point to be stressed is that our two cases
of vismodegib resistance occurred in patients who had not
received previous radiation therapy. We cannot exclude
that Hh inhibitor resistance outbreak could be higher in pa-
tients having received a radiation insult, as well as it is
possible that alternative therapeutic schedules may alter
resistance mechanism development. (Buonamici et al.,
2010).
In this report we discussed two different SMO mutations
representing examples of primary or secondary resistance
respectively to vismodegib in two distinct BCC cases. The
screening for the reported SMO mutations and the search for
new therapeutic strategies to overcome related resistance
mechanisms represent a priority in the treatment of patients
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